Scarica l'app Stockscreener
42.27
2.31%
-1.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$43.69
Aprire:
$43.92
Volume 24 ore:
72,569
Relative Volume:
0.20
Capitalizzazione di mercato:
$2.10B
Reddito:
$264.38M
Utile/perdita netta:
$-109.16M
Rapporto P/E:
-9.8398
EPS:
-4.2958
Flusso di cassa netto:
$-39.22M
1 W Prestazione:
-7.74%
1M Prestazione:
+8.46%
6M Prestazione:
+65.49%
1 anno Prestazione:
+33.38%
Intervallo 1D:
$42.30
$44.12
Intervallo di 1 settimana:
$40.80
$46.80
Portata 52W:
$23.14
$48.89
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| MIRM | 42.51 | 2.10B | 264.38M | -109.16M | -39.22M | -4.2958 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.20 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.50 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - MSN
Phocas Financial Corp. Has $1.48 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Decreased by First Turn Management LLC - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 4.6% After Insider Selling - MarketBeat
MIRM FY2024 EPS Estimate Raised by Cantor Fitzgerald - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of Stock - MarketBeat
Mirum Pharmaceuticals SVP sells $117,752 in stock - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results - Simply Wall St
HC Wainwright Has Positive Estimate for MIRM FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for MIRM FY2024 Earnings - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Quarterly 10-Q Report - Quartzy
Janus Henderson Group PLC's Strategic Adjustment in Mirum Pharma - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Mirum Pharmac - GuruFocus.com
HC Wainwright Issues Pessimistic Estimate for MIRM Earnings - MarketBeat
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting - Business Wire
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Mirum shares target lifted on raised sales guidance and strong LIVMARLI sales - Investing.com Canada
How To Trade (MIRM) - Stock Traders Daily
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $50.00 - MarketBeat
Mirum Pharmaceuticals stock hits all-time high of $45.28 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high of $45.28 - Investing.com
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth - TipRanks
MIRMMirum Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results - Investing.com
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results By Investing.com - Investing.com Australia
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by GSA Capital Partners LLP - MarketBeat
Mirum Pharmaceuticals earnings beat by $0.15, revenue topped estimates - Investing.com UK
Earnings Outlook For Mirum Pharmaceuticals - Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharma Grants 56K Stock Options, 28K RSUs in Key Employee Retention Move | MIRM Stock News - StockTitan
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Mirum’s liver disease drug candidate gets FDA breakthrough designation - MSN
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Mirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on Tuesday - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Business Wire
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know - MSN
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - BioSpace
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth - Insider Monkey
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):